SCHEMBL1206338

SCHEMBL1206338

O=Cc1ccc(C(=O)N2Cc3ccccc3C2=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 3/20 0.44
KCNN4 O15554 1/20 0.43
KCNA3 P22001 1/20 0.43
ACHE P22303 2/20 0.41
BACE1 P56817 2/20 0.41
ALOX15 P16050 3/20 0.40
TSHR P16473 2/20 0.40
SIRT1 Q96EB6 1/20 0.40
ALDH1A1 P00352 3/20 0.40
XIAP P98170 1/20 0.40
HKDC1 Q2TB90 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1201562 0.85 UNG (0.45) KDM4ESMN1; SMN2HTTKMT2AKCNN4
SCHEMBL8723658 0.80 KDM4E (0.44) KDM4ESMN1; SMN2HTTKMT2AKCNN4
SCHEMBL8723662 0.80 KMT2A (0.45) KDM4ESMN1; SMN2HTTKMT2AKCNN4
SCHEMBL6391108 0.79 KDM4E (0.45) KDM4ESMN1; SMN2HTTKMT2AKCNN4
SCHEMBL27840846 0.78 ACHE (0.47) KDM4ESMN1; SMN2HTTKMT2AKCNN4
SCHEMBL1179178 0.78 HTT (0.44) KDM4ESMN1; SMN2HTTKMT2AKCNN4
SCHEMBL3241682 0.77 KMT2A (0.46) KDM4ESMN1; SMN2HTTKMT2AKCNN4
SCHEMBL15486904 0.75 ACHE (0.44) KDM4ESMN1; SMN2HTTKMT2AKCNN4
SCHEMBL1200850 0.74 ACHE (0.46) KDM4ESMN1; SMN2HTTKMT2AKCNN4
SCHEMBL3249783 0.74 HSP90AA1 (0.45) KDM4ESMN1; SMN2HTTKMT2AKCNN4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1724263-B1 BASIC AMINE COMPOUND AND USE THEREOF KUREHA CORP (JP) 2014-03-05 EP disclosed
US-20110172212-A1 AMINE-BASED COMPOUND AND USE THEREOF KUREHA CORPORATION (JP) 2011-07-14 US disclosed
US-7932281-B2 Amine-based compound and use thereof KUREHA CORPORATION (JP) 2011-04-26 US disclosed
US-20110046113-A1 AMINE COMPOUND AND USE THEREOF KUREHA CORPORATION (JP) 2011-02-24 US disclosed
US-7833991-B2 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists KUREHA CORPORATION (JP) 2010-11-16 US disclosed
US-20070208007-A1 Amine-Based Compound and Use Thereof KUREHA CORPORATION (JP) 2007-09-06 US disclosed
US-20070208033-A1 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists KUREHA CORPORATION (JP) 2007-09-06 US disclosed
US-7176227-B2 For example, N-(4-{[bis(1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-N',N'-dipropylbutane-1,4-diamine; efficacious against diseases such as infection with HIV virus, rheumatism, and cancer metastasis KUREHA CORPORATION (JP) 2007-02-13 US disclosed
EP-1724263-A1 BASIC AMINE COMPOUND AND USE THEREOF Kureha Corporation (JP) 2006-11-22 EP disclosed
US-20050165063-A1 Amine compounds and use thereof KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED. (JP) 2005-07-28 US disclosed
EP-1550657-A1 AMINE COMPOUNDS AND USE THEREOF Kureha Chemical Industry Co., Ltd. (JP) 2005-07-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172212-A1 AMINE-BASED COMPOUND AND USE THEREOF NR0B2, NR5A2, NR1D2 KDM4E 2406/4885SMN1; SMN2 2498/4885HTT 3655/4885
US-20050165063-A1 Amine compounds and use thereof NR0B2, NR5A2, NR1H4 KDM4E 2589/4885SMN1; SMN2 3310/4885HTT 3354/4885
US-20110046113-A1 AMINE COMPOUND AND USE THEREOF NR0B2, NR1D2, NR0B1 KDM4E 2192/4885SMN1; SMN2 3021/4885HTT 3987/4885
US-20070208007-A1 Amine-Based Compound and Use Thereof NR0B2, NR5A2, NR2E1 KDM4E 2871/4885SMN1; SMN2 2494/4885HTT 3429/4885
US-20070208033-A1 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists CXCR4, CXCR6, CCR5 KDM4E 2675/4885SMN1; SMN2 3683/4885HTT 4522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.